Search

Your search keyword '"Matucci Cerinic M"' showing total 2,359 results

Search Constraints

Start Over You searched for: Author "Matucci Cerinic M" Remove constraint Author: "Matucci Cerinic M"
2,359 results on '"Matucci Cerinic M"'

Search Results

1. Systematic Literature Review and Expert Opinion for the Use of Viscosupplementation with Hyaluronic Acid in Different Localizations of Osteoarthritis

3. Low-dose modified-release prednisone in axial spondyloarthritis: 3-month efficacy and tolerability

5. Clinical significance of the anti-Nucleolar Organizer Region 90 antibodies (NOR90) in systemic sclerosis: Analysis of the European Scleroderma Trials and Research (EUSTAR) cohort and a systematic literature review

7. POS0821 MENOPAUSE AND SYSTEMIC SCLEROSIS: THE LINK BETWEEN MENOPAUSAL AGE, DISEASE ONSET AND CLINICAL MANIFESTATIONS IN AN ANALYSIS OF THE SPRING-SIR REGISTRY

10. AB1183 THE USE OF MYCOPHENOLATE MOFETIL IN LIMITED CUTANEOUS SYSTEMIC SCLEROSIS IS ASSOCIATED WITH A REDUCED RISK OF VASCULAR COMPLICATIONS REQUIRING PHARMACOLOGICAL INTERVENTION UPGRADES

11. POS1479-HPR TRAVEL DISTANCE TO TERTIARY HEALTHCARE REFLECTS DISEASE SEVERITY AND MEDICATION ACCESS IN SYSTEMIC SCLEROSIS PATIENTS: INSIGHTS FROM THE ITALIAN SPRING REGISTRY

12. POS0235 NEW ONSET OF INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS: CLINICAL COURSE AND OUTCOMES FROM A EUSTAR DATABASE ANALYSIS

13. POS0211 PAH TREATMENT AT TIME OF DIAGNOSIS IS ASSOCIATED WITH IMPROVED SURVIVAL REGARDLESS OF HEMODYNAMIC THRESHOLDS AND RISK STRATIFICATION - A EUSTAR ANALYSIS

14. POS1099 DIFFICULT-TO-TREAT MANIFESTATIONS OF GRANULOMATOSIS WITH POLYANGIITIS. A EUROPEAN MULTICENTRE STUDY ON SUBGLOTTIC STENOSIS

15. AB1196 BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS IN SUBJECTS WITH ILD IN A PHASE 2 STUDY TO EVALUATE EFFICACY, SAFETY, AND TOLERABILITY OF MT-7117 IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS

16. AB1189 THE CIRCULATING LEVELS OF ENDOGENOUS EICOSAPENTAENOIC ACID AND DOCOSAHEXAENOIC ACID-DERIVED RESOLVINS ARE INCREASED IN SYSTEMIC SCLEROSIS: EVIDENCE FROM A SINGLE CENTRE COHORT

17. POS0832 IMMUNOSUPPRESSION VERSUS COMBINATION OF IMMUNOSUPPRESSION AND ORAL GLUCOCORTICOIDS FOR SKIN FIBROSIS IN EARLY DIFFUSE SYSTEMIC SCLEROSIS PATIENTS. A TARGET TRIAL EMULATION STUDY FROM THE EUSTAR DATABASE

21. POS0842 PRIMARY HEART INVOLVEMENT IN SYSTEMIC SCLEROSIS: THE ROLE OF VENTRICULAR ECTOPIC BEATS AS RED FLAGS FOR ACTIVE MYOCARDIAL INFLAMMATION DETECTED AT CARDIAC MAGNETIC RESONANCE

22. POS0044 DECIPHERING THE GUT MICROBIOTA OF VERY EARLY SYSTEMIC SCLEROSIS (VEDOSS) PATIENTS: A TAXONOMIC AND FUNCTIONAL CHARACTERIZATION

23. OP0265 RITUXIMAB RETENTION RATE IN SYSTEMIC SCLEROSIS: A REAL-LIFE ITALIAN MULTICENTER STUDY

24. OP0225 CHANGES IN TREATMENT PATTERNS AND THEIR INFLUENCE ON THE OUTCOME OF SYSTEMIC SCLEROSIS-INTERSTITIAL LUNG DISEASE (SSc-ILD) PATIENTS: AN EUSTAR ANALYSIS

25. POS0826 PREDICTORS OF RESPONSE AND LONG-TERM EFFICACY AND SAFETY OF NINTEDANIB IN SYSTEMIC SCLEROSIS-INTERSTITIAL LUNG DISEASE: DATA FROM AN ITALIAN MULTICENTRE STUDY

27. OP0073 UNRAVELING PATHOPHYSIOLOGY AND HEMATOPOIESIS OF VEXAS SYNDROME BY MULTI-OMICS ANALYSIS AND TARGETED GENE EDITING

28. POS0843 IMMUNOSUPPRESSIVE THERAPY TO TREAT NEWLY DIAGNOSED PRIMARY HEART INVOLVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS: AN ITALIAN CARDIAC MAGNETIC RESONANCE BASED STUDY

32. POS0432 DRIVERS OF DISEASE BURDEN IN PATIENTS WITH SYSTEMIC SCLEROSIS ACROSS CLINICAL AND DEMOGRAPHIC SUBGROUPS REVEALED BY THE EULAR SYSTEMIC SCLEROSIS IMPACT OF DISEASE (ScleroID) QUESTIONNAIRE

33. Systemic sclerosis sine scleroderma: clinical and serological features and relationship with other cutaneous subsets in a large series of patients from the national registry 'SPRING' of the Italian Society for Rheumatology

34. Systemic sclerosis sine scleroderma: clinical and serological features and relationship with other cutaneous subsets in a large series of patients from the national registry 'SPRING' of the Italian Society for Rheumatology

38. The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET

39. Geographical heterogeneity of clinical and serological phenotypes of systemic sclerosis observed at tertiary referral centres. The experience of the Italian SIR-SPRING registry and review of the world literature

40. Sex-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study From the National Registry of the Italian Society for Rheumatology

41. Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies

42. Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher/European Scleroderma Trials and Research group (EUSTAR) survey

43. Consensus on the assessment of systemic sclerosis–associated primary heart involvement: World Scleroderma Foundation/Heart Failure Association guidance on screening, diagnosis, and follow-up assessment

44. Cardiac inflammation and fibrosis patterns in systemic sclerosis, evaluated by magnetic resonance imaging: An update.

45. Systemic sclerosis sine scleroderma: clinical and serological features and relationship with other cutaneous subsets in a large series of patients from the national registry 'SPRING' of the Italian Society for Rheumatology

46. Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study

47. Lung vascular changes as biomarkers of severity in systemic sclerosis-associated interstitial lung disease

48. Myelomonocytic cells in giant cell arteritis activate trained immunity programs sustaining inflammation and cytokine production

49. Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase

Catalog

Books, media, physical & digital resources